Press Releases

BioReference Laboratories, Inc. Announces Contract with Corizon, Inc. to Provide Correctional Healthcare Laboratory Services

Bio-Reference Laboratories, Inc. announced that effective January 1, 2012, it has entered into a new Master Agreement to provide diagnostic laboratory services for some of the facilities that Corizon, Inc. services around the country providing contract healthcare services...

A New Resource That Offers Personalized Nutritional Guidance to Achieve Better Health

Millions of resolutions come with every New Year, many of which are to get healthy. But, there's a lot of confusion around what constitutes healthy nutrition, which is a key piece of the puzzle. ...

Kelly Brush Foundation Awards $100K Support For Ski Racing Safety and Adaptive Sports

The Kelly Brush Foundation awarded $100,514 in grants for spinal cord injury prevention at the end of 2011 enriching the lives of those with spinal cord injuries and furthering the foundation's mission to improve ski racing safety, Kelly Brush...

Bristol-Myers Squibb to Acquire Inhibitex

Bristol-Myers Squibb Company (NYSE:BMY) and Inhibitex, Inc. (Nasdaq:INHX) have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger. ...

Expert plastic surgeon offers free removal of PIP implants

Following the latest news that there is to be a government review of the French Poly Implant Prothese (PIP) implants Consultant Breast Surgeon, Professor Kefah Mokbel who specialises in mastectomy and breast reconstructive surgery following breast cancer, has...

Gilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting Period

Gilead Sciences, Inc. today announced that it has received early termination of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Gilead’s cash tender offer for Pharmasset, Inc . ...

Synta Pharmaceuticals Prices Public Offering of Common Stock

Synta Pharmaceuticals Corp. announced today that it has priced an underwritten public offering of 7,000,000 shares of its common stock at a price to the public of $4.40 per share. Net proceeds to Synta...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read